Open AccessETOILE: Real-World Evidence of 24 Months of Ranibizumab 0.5 mg in Patients with Visual Impairment Due to Diabetic Macular Edema
Author(s) -
Laurent Kodjikian,
A. Lecleire–Collet,
Corinne Dot,
MarieLaure Le Lez,
Stéphanie Baillif,
Ali Erginay,
Eric H. Souied,
E. Fourmaux,
Philippe Gain,
Anne Ponthieux
Publication year - 2021
Publication title -
clinical ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 56
eISSN - 1177-5483
pISSN - 1177-5467
DOI - 10.2147/opth.s313081
Subject(s) - medicine , ranibizumab , diabetic macular edema , visual acuity , ophthalmology , observational study , retinal , diabetic retinopathy , bevacizumab , diabetes mellitus , chemotherapy , endocrinology
To evaluate the real-world effectiveness of intravitreal ranibizumab 0.5 mg (Lucentis) in improving visual acuity (VA) in adults with decreased VA due to diabetic macular edema (DME).